Moderna, Inc. (ETR:0QF)
| Market Cap | 13.56B -13.4% |
| Revenue (ttm) | 1.90B -56.1% |
| Net Income | -2.66B |
| EPS | -6.86 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,785 |
| Average Volume | 30,307 |
| Open | 34.41 |
| Previous Close | 36.29 |
| Day's Range | 33.45 - 35.18 |
| 52-Week Range | 19.37 - 46.96 |
| Beta | 1.34 |
| RSI | 48.48 |
| Earnings Date | Feb 13, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline
Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline
Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling
What's next for the vaccine giant?
RSP, SNDK, WDC, MRNA: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Equal Weight ETF (Symbol: RSP) where we have detected ...
Interesting MRNA Put And Call Options For March 27th
Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the March 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA options ...
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX) , expanding its lineup of single-stock leveraged ETFs designed f...
TD Waterhouse Canada Inc. Sells 534 Shares of Moderna Inc (MRNA)
TD Waterhouse Canada Inc. Sells 534 Shares of Moderna Inc (MRNA)
CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery
Moderna CEO Stéphane Bancel discusses positive cancer vaccine trial results and the impact GLP-1 drugs on 'Mornings with Maria.' #foxbiusiness #morningswithmaria
Moderna said revenue would grow in 2026 for the first time since 2021, says Jim Cramer
'Mad Money' host Jim Cramer looks back at the S&P 500 winner in January.
Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings
Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal Battle with Moderna
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal Battle with Moderna
Arbutus jumps on ruling in patent dispute with Moderna
Goldman Sachs Innovate Equity ETF Buys 2,395 Shares of Moderna Inc (MRNA)
Goldman Sachs Innovate Equity ETF Buys 2,395 Shares of Moderna Inc (MRNA)
PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)
PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)
Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)
Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)
Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade)
Noteworthy Friday Option Activity: V, MRNA, WDC
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Visa Inc (Symbol: V), where a total of 45,386 contracts have traded so far, representing approxi...
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift
Moderna announces departure of medical chief
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi ...
Moderna CMO Jacqueline Miller to step down
Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.
Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Offi...
Dr. David Berman to Join Moderna as Chief Development Officer
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...
Dr. David Berman to Join Moderna as Chief Development Officer
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...
Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing
Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
mRNA-3927 is a strong strategic fit with Recordati's rare Metabolic portfolio Collaboration combines Moderna's expertise in mRNA technology for rare metabolic disorders with Recordati's established gl...